Celiac Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Celiac disease is an immune-mediated
disorder characterized by small intestinal enteropathy, systemic malabsorption
and immune activation symptoms, and autoantibodies to tissue transglutaminase
(TTG). It is unique among autoimmune diseases in that the trigger, dietary gluten,
has been identified, and removing it results in the resolution of symptoms and
enteropathy in most patients. The undiagnosed celiac disease might have severe
consequences in children and adult subjects. Celiac disease's primary mechanism
is an abnormal adaptive immune response to gluten-derived peptides. Prolamines
have been found to contain critical epitopes presented by either HLA-DQ2 or
HLA-DQ8 that induce a CD4+ T-lymphocyte response. Celiac disease can be severe
as it can cause long-lasting digestive problems and keep the body from getting
all the necessary nutrients. It can also affect the body outside the intestine.
- The prevalence of Celiac disease varies from 450 to 675 cases
per 100,000 population in the USA.
Thelansis’s “Celiac Disease Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Celiac
Disease treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Celiac Disease across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Celiac Disease Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment